Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469839 | 1.00 | CA2 (0.57) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL21962105 | 0.88 | PKM (0.59) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL10780912 | 0.86 | CA1 (0.54) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL35406099 | 0.86 | PKM (0.54) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL5189382 | 0.86 | PKM (0.54) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL27856555 | 0.86 | CA1 (0.57) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL10710253 | 0.84 | SMN1; SMN2 (0.62) | CA2CA9CA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8048512 | 0.83 | PKM (0.51) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL28022375 | 0.83 | PKM (0.55) | CA2CA9CA1PKMALDH1A1 | |
| SCHEMBL31525849 | 0.82 | PKM (0.50) | CA2CA9CA1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0170164-B1 | SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1988-10-05 | — | — | EP | claimed |
| US-H122-H | PYRAZOLOAZOLE-TYPE MAGENTA COUPLER DISPERSED IN A HIGH-BOILING PHOSPHATE SOLVENT | FUJI PHOTO FILM CO., LTD. (JP) | 1986-09-02 | — | — | US | claimed |
| EP-0170164-A2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1986-02-05 | — | — | EP | claimed |
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-0170164-A2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1986-02-05 | — | — | EP | disclosed |
| US-4559297-A | DISCOLORATION INHIBITION | FUJI PHOTO FILM CO., LTD. (JP) | 1985-12-17 | — | — | US | disclosed |
| EP-0164130-A2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-12-11 | — | — | EP | disclosed |
| US-4540654-A | Method of forming color image comprising heterocyclic magenta dye-forming coupler | FUJI PHOTO FILM CO., LTD. (JP) | 1985-09-10 | — | — | US | disclosed |
| EP-0135860-A2 | Derivatives of 6-sulfoxyphenol, their preparation and their use as cytoprotectors; use of derivatives of salicylaldehyde as cytoprotectors | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-03 | — | — | EP | disclosed |
| US-4500630-A | USING AN IMIDAZOLO(1,2-B)PYRAZOLE COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1985-02-19 | — | — | US | disclosed |
| EP-0119741-A2 | Method of producing magenta images in silver halide colour photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1984-09-26 | — | — | EP | disclosed |
| EP-0119860-A2 | Pyrazolo magenta couplers used in silver halide photography | FUJI PHOTO FILM CO., LTD. (JP) | 1984-09-26 | — | — | EP | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CA2 2985/4885CA9 2304/4885CA1 2072/4885 |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CA2 2884/4885CA9 2045/4885CA1 1716/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | CA2 2884/4885CA9 2045/4885CA1 1716/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CA2 2865/4885CA9 1575/4885CA1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.